Background and Purpose-Proximal large vessel occlusion (LVO) is present in up to 30% of minor strokes. The effectiveness of mechanical thrombectomy (MT) in the subgroup of minor stroke with LVO in the anterior circulation is still open to debate. Data about MT in this subgroup of patients are sparse, and their optimal management has not yet been defined. The purpose of this multicenter cohort study was to evaluate the effectiveness of MT in patients experiencing acute ischemic stroke (AIS) because of LVO in the anterior circulation, presenting with minor-to-mild stroke symptoms (National Institutes of Health Stroke Scale score of <8). Methods-Multicenter cohort study involving 4 comprehensive stroke centers having 2 therapeutic approaches (urgent thrombectomy associated with best medical treatment [BMT] versus BMT first and MT if worsening occurs) about management of patients with minor and mild acute ischemic stroke harboring LVO in the anterior circulation. An intentionto-treat analysis was conducted. The primary end point was the rate of excellent outcome defined as the achievement of a modified Rankin Scale score of 0 to 1 at 3 months. Results-Three hundred one patients were included, 170 with urgent MT associated with BMT, and 131 with BMT alone as first-line treatment. Patients treated with MT were younger, more often received intravenous thrombolysis, and had shorter time to imaging. Twenty-four patients (18.0%) in the medical group had rescue MT because of neurological worsening. Overall, excellent outcome was achieved in 64.5% of patients, with no difference between the 2 groups. Stratified analysis according to key subgroups did not find heterogeneity in the treatment effect size. Conclusions-Minor-to-mild stroke patients with LVO achieved excellent and favorable functional outcomes at 3 months in similar proportions between urgent MT versus delayed MT associated with BMT. There is thus an urgent need for randomized trials to define the effectiveness of MT in this patient subgroup.
S ince 2015, 6 randomized controlled trials have demonstrated the superiority of mechanical thrombectomy (MT) over standard medical care in patients with acute ischemic stroke (AIS) caused by occlusion of arteries of the proximal anterior circulation. 1, 2 The American Heart Association gives a level 1a evidence-based score for MT only for patients with baseline National Institutes of Health Stroke Scale (NIHSS) score of ≥6, because a majority of positive trials enrolled patients above this threshold, 1 even if patients with low NIHSS could have been included in some randomized controlled trials. 3, 4 Thus, the median NIHSS in the 5 first randomized controlled trials was 17. 1 Although there was no effect modification by NIHSS observed among patients enrolled in the HERMES meta-analysis (Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials), 1 the superiority of MT in minor stroke is not proven.
However, minor or mild stroke is not a benign condition, with about one-third of patients with minor stroke having persistent disability at 90 days, [5] [6] [7] not being discharged home, 8 or unable to walk independently at discharge. 8 It is not a rare entity, with about two-thirds of patients with stroke presenting with minor-to-mild symptoms in populationbased studies. 9 Furthermore, patients with proximal occlusions may present with low NIHSS, 10 and such an occlusion is associated in observational studies with a high risk of both clinical worsening and bad outcome. 11 Although there is controversy on the association of the NIHSS score to predict arterial occlusion, it has been shown that large vessel occlusion (LVO) could be present in about 18% of patients with NIHSS between 0 and 4, 39% for patients with NIHSS between 5 and 8. 12 The purpose of this multicenter cohort study was to compare best medical treatment (BMT)+immediate MT versus BMT alone in patients with acute minor (NIHSS score of ≤3) to mild (NIHSS score of <8) stroke symptoms and LVO in the anterior circulation admitted to 4 comprehensive stroke centers (CSCs).
Materials and Methods

Study Design
We performed a multicenter cohort study with data extraction from 4 French prospective clinical registries of consecutive patients admitted in CSCs for AIS. The local ethics committees approved the use of patient data for this retrospective analysis.
Consecutive AIS patients with proximal intracranial LVO involving the anterior circulation with minor-to-mild stroke symptoms were compared, according to whether they received MT associated with BMT (case group) or BMT alone (control group) during the acute phase.
Inclusion Criteria
Consecutive patients were included if they fulfilled the following criteria: (1) AIS confirmed with cerebral imaging with NIHSS score of <8 at admission; (2) Middle cerebral artery M1, proximal M2 segment, intracranial internal carotid artery, cervical carotid or tandem occlusion; and (3) Acute artery occlusion confirmed on cerebral magnetic resonance imaging (MRI) or angio-CT. Exclusion criteria were the following: (1) Patients without primary functional independence (mRS score of >2); (2) Patients with nonocclusive thrombus; and (3) Patients with distal M2 occlusion, that is, branch occlusion beyond the midpart of the insula.
Patient Management
Two different approaches about the management of minor or mild stroke patients (MMSP) harboring LVO in the anterior circulation were systematically conducted in the 4 CSC involved in this study:
1. Endovascular group: MT in first instance: center 1, 2, and 3.
MT was systematically associated with BMT according current guidelines. 2. BMT group: BMT in first instance according current guidelines: center 4. MT was possible if worsening occurs (rescue). All the participating centers could admit patients from remote centers.
Further details on patient management are available in the onlineonly Data Supplement.
Patient Characteristics
Patient characteristics were prospectively collected on arrival at the CSC by the stroke neurologist: (1) clinical: age, sex, cardiovascular risk factors (hypertension, dyslipidemia, diabetes mellitus, and active smoking habits), current medication, time from symptom onset, NIHSS at baseline, use of intravenous thrombolytics, time of intravenous thrombolysis, time of MT and (2) imaging: time from symptoms onset to imaging, the Alberta Stroke Program Early Computed Tomography (CT) Score on diffusion-weighted MRI Alberta Stroke Program Early CT Score or CT was calculated by a neuroradiologist blinded to treatment. The arterial occlusion site was defined according to Fischer classification, that designates the M1 segment terminating at the genu where the middle cerebral artery turns around the limen insulae. Patients with a combined M1 and M2 occlusion were categorized as belonging to the M1 occlusion group.
All occlusions were defined according 2 readers, both blinded to the clinical outcome.
After an exhaustive in-hospital workup, stroke etiology was defined, according to the TOAST classification (Trial of ORG 10172 in Acute Stroke Treatment).
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Follow-Up and Outcome
All patients were hospitalized in the neurological ICU for at least 24 hours after admission and underwent cross-sectional imaging (CT or MRI) within 18 to 24 hours after admission. Intracranial hemorrhage (ICH) was classified according to the European Cooperative Acute Stroke Study criteria. Patients were evaluated 24 hours after the procedure and symptomatic ICH was defined as any ICH with an increase of at least 4 NIHSS points within 24 hours, or resulting in death. The modified Rankin Scale (mRS) at 90 days was assessed by stroke neurologists or trained research nurses unaware of the initial treatment, during face-to-face interviews or via telephone conversations with the patients, their relatives or their general practitioners.
The primary study outcome was the achievement of an mRS score of 0 to 1 at 3 months (excellent outcome). Secondary outcomes included favorable outcome (defined as an mRS score of 0-2), perfect outcome (mRS 0), all-cause mortality at 90 days, and any ICH.
Statistical Analysis
Quantitative variables are expressed as means (SD) in the case of normal distribution or medians (interquartile range) otherwise. Categorical variables are expressed as numbers (%). Normality of distributions was assessed using histograms and the Shapiro-Wilk test. Baseline characteristics were described according the treatment group and the magnitude of the between-group differences was assessed by calculating the absolute standardized difference; an absolute standardized difference <20% was interpreted as a small difference. 14 We assessed the effect of the therapeutic approach (endovascular versus medical) on clinical outcomes using logistic regression models and calculated the odds ratio (OR) for the endovascular relative to the medical group as the treatment effect size. To reduce the effects of potential confounding factors in the between-group comparisons, we used propensity-score methods. 15 Further details concerning the propensity score are available in the online-only Data Supplement.
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Our first analyses covered the whole study group according to an intention-to-treat principle. All analyses were repeated after excluding patients who did not receive endovascular treatment from the endovascular-approach group and those who received adjunctive endovascular treatment from the medical-approach group (defined as a sensitivity per-protocol analysis). We also reported a sensitivity analysis restricted to patients with minor stroke defined as admission NIHSS score of <6.
Finally, we investigated the heterogeneity in treatment effect size for primary outcome across the following subgroups: age (<70 versus ≥70 years), admission NIHSS (<4 versus ≥4), prior use of intravenous thrombolysis, (yes versus no), and site of occlusion (isolated middle cerebral artery versus others). Heterogeneity across subgroups was quantified by introducing a multiplicative term into logistic regression models. Subgroup analyses were performed for the whole study group, both in propensity score-matched and propensity score-adjusted cohorts.
Statistical testing was conducted at the 2-tailed α-level of 0.05. Data were analyzed using the SAS software version 9.3 (SAS Institute, Cary, NC).
Results
Population and Participating Centers
From January 2013 to March 2016, a total of 1271 patients with an arterial occlusion in the anterior circulation were treated by endovascular therapy at 3 CSCs (center 1, 2, 3). Of these, 1094 with NIHSS score of ≥8, 2 with prestroke mRS score of >2, and 5 lost to follow-up were excluded (Figure 1 ), resulting in a final sample size of 170 patients in this group (case group). In the same period, 1660 AIS patients were admitted to the center with the medical approach (center 4). Of these, 1513 patients not responding to inclusion criteria (no LVO or LVO with NIHSS score of ≥8, lacunar infarcts, infarcts in the posterior circulation) were excluded. Among the 147 remaining patients, 16 were excluded (prestroke mRS score of >2, n=2; distal M2 occlusion, n=9; lost to follow-up, n=5), resulting in a final sample size of 131 patients in this group (control group).
The Table shows the baseline characteristics according to the 2 study groups before and after propensity score-matching.
Before matching, several meaningful differences (absolute standardized difference >20%) were found. Patients treated with the endovascular approach were younger, had less frequently hypercholesterolemia, left-sided and middle cerebral artery-M2 occlusion, had greater NIHSS values and were treated by IVT more frequently than patients treated by the medical approach. In addition, a greater time from symptoms onset to brain imaging was observed (median [interquartile range]: 128 [94-184] minutes in the endovascular group versus 169 [122-275] minutes in the medical group). These differences were reduced after propensity score-matching ( Figure I in the online-only Data Supplement), with an absolute standardized difference >10% only for time to brain imaging (16.0%) suggesting that the 2 study groups were well balanced after matching.
In the case group, 33 patients (19.4%) did not receive endovascular treatment because of substantial reperfusion on the first angiogram (n=24), failure of catheterization (n=3), clinical recovery (n=2), or intracranial stenosis without occlusion (n=4). In the control group, 24 patients (18.3%) received adjunctive endovascular treatment because of early neurological worsening (rescue therapy). The baseline characteristics of the study sample excluding these 57 patients (defined as perprotocol analysis) are described in Table I in the online-only Data Supplement. The endovascular procedure characteristics (onset to groin puncture time, number of passes, successful recanalization rate, groin puncture to recanalization time, and complications) are available in Table II in the online-only Data Supplement.
Outcome and Therapeutic Approach
Excellent outcome (our primary outcome) was achieved in 63.5% (n=191) of patients overall, with no difference between the 2 groups, with an unadjusted OR of 1.15 (95% confidence interval [CI], 0.72-1.86) for the endovascular relative to the medical group. In both propensity score-matched and propensity score-adjusted cohorts, no difference in excellent outcome was found (Figure 2) . A similar result was found when considering favorable outcome, whereas patients treated with the endovascular approach had a perfect outcome significantly more often than those receiving the medical approach (adjusted OR, 1.72; 95% CI, 1.05-2.81). However, this difference remained significant only in the propensity score-adjusted cohort (Figure 1 ; adjusted OR, 1.79; 95% CI, 1.02-3.14). About safety outcome, all-cause mortality within 90-days after symptom onset occurred in 5.0% of patients (n=15) with no difference between the 2 groups ( Figure 2) . However, any ICH occurred more frequently in patients from the endovascular group compared with the medical group (16.5% versus 6.1%, P=0.008). This difference remained nonsignificant in the propensity score-matched cohort (OR, 2.63; 95% CI, 0.86-8.02) as well as in the propensity scoreadjusted cohort (OR, 1.84; 95% CI, 0.76-4.47). Among the ICH cases, only 3 were symptomatic (1 in the medical and 2 in the endovascular group). Similar findings were found when analysis was restricted to minor stroke patients with admission NIHSS score of <6 (Table III and In sensitivity analysis restricted to our per-protocol sample ( Figure II in the online-only Data Supplement), the endovascular group was only significantly associated with a higher ICH rate in the propensity score-matched cohort (OR, 3.95; 95% CI, 1.02-15.25); the corresponding propensity scoreadjusted OR was 2.96 (95% CI, 0.91-9.62; P=0.072).
When the analysis in primary outcome (main sample) was stratified according to key subgroups, we found no significant heterogeneity in the treatment effect size (Figure 3 ). In the propensity score-adjusted cohort, only a tendency toward better outcomes with the endovascular approach was observed for patients with the more proximal occlusions (adjusted OR, 2.23; 95% CI, 0.78-6.33; P=0.13).
Discussion
Main Results and Literature
Our study suggests that acute stroke patients with NIHSS score of <8 and occlusion in the anterior circulation, having had MT or BMT, achieved excellent (65.9% and 62.6%, respectively) and favorable (81.2% and 74.8%) outcomes in similar proportions.
A recent observational multicenter study showed that in patients with minor stroke symptoms (NIHSS score of ≤4) receiving BMT, a high rate of excellent outcome (77%) could be achieved. 16 Although the global rate of excellent outcome was lower in our study (64.5%), all patients included harbored LVO at admission, which differs with the 28% of the study cited above. Clinical worsening leading to MT occurred in a substantial proportion (18.3%) of patients belonging to the medical group in our study. One previous study has shown that neurological deterioration occurred in about 23% of nonthrombolyzed and in about 10% of thrombolyzed minor stroke patients (NIHSS score of ≤5) harboring LVO in the anterior circulation. 17 Thus, careful clinical monitoring in intensive stroke care units, including repeated NIHSS, is mandatory for MMSP with LVO, to consider rescue therapy when facing clinical worsening. We should note that rescue therapy seems associated to less good results than MT performed in first instance in this subset of patients. Values expressed as numbers (%) unless otherwise indicated. ASD, absolute standardized difference; ASPECTS, Alberta stroke program early computed tomography score; ICA, internal carotid artery; IQR, interquartile range; MCA, middle cerebral artery; and NIHSS, National Institutes of Health Stroke Scale.
*Calculated after handling missing data (prior use of intravenous thrombolysis, n=2; ASPECT, n=32; time from symptom onset to imaging, n=38) using multiple imputation procedure. †Estimated using the rank-transformed data.
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Our study has several strengths. First, it is the largest observational study comparing MT associated with BMT and BMT alone in MMSP. There is some evidence suggesting that MMSP harboring LVO in the anterior circulation should not be considered as minor strokes with benign evolution. First, intracranial occlusion is a known risk factor of early neurological deterioration, which is not uncommon in MMSP harboring LVO. 18 Second, the more proximal the occlusion, the more the patient is at risk. 11 Our findings are in line with these data, with 1/3 of patients in the medical group having undergone rescue MT harboring carotid or tandem occlusions. Second, we compared 2 systematic approaches, with endovascular treatment conducted for 80.6% of patients belonging to the endovascular group, and BMT conducted for 81.7% of patients belonging to the medical group.
The recent enthusiasm concerning MT has led to consideration of this technique for use in MMSP harboring LVO. 19 However, according to the latest meta-analysis of randomized controlled trials, 1 there is no proven efficacy of MT in the subgroup of minor stroke and, as a consequence, the American Heart Association gives a level 1a evidencebased score only for MT performed in patients with baseline NIHSS score of ≥6.
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Some data, from observational studies, suggested that MT could be effective in MMSP with LVO. A recent study with a limited number of patients has shown that MT could lead to a shift toward a lower NIHSS in patients with LVO presenting with minimal stroke symptoms. 21 Another retrospective study has already evaluated MT in this group of patients, without any control group. 22 There is also some data suggesting that MT could be safe and effective on selected patients, especially those presenting early neurological deterioration. 23 Our findings temper the results from the studies cited above and are in line with a previous small study. 24 We should note that in the intention-to-treat analysis, perfect outcome (mRS score of 0) was achieved more often for patients having undergone MT in first instance (39.4% versus 27.5%). However, this outcome is rarely used in stroke trials. 25 
Population
Concerning patient selection, our thresholds correspond to those used in several studies, both for minor (NIHSS score of ≤3) 26, 27 and mild strokes (NIHSS score of <8). 28 One of the reasons for this NIHSS cutoff was the involvement of one center in the SWIFT-PRIME study, enrolling patients with NIHSS score of ≥8. 29 Because some authors consider NIHSS score of <6 as minor strokes, we provide an analysis focused on this threshold (given in the online-only Data Supplement).
Limits and Urgent Need for Randomized Studies
Study Design
The main limitation of our study is its nonrandomized design, with differences in baseline characteristics (age, stroke severity, infarct side, delays, and use of IVT) linked to this retrospective design. Especially, admission biases are hard to rule out, given that many patients having had MT in first instance were addressed from remote centers. We cannot rule out center specific differences. One center only contributed to the BMT in first instance group, and although management in this center was performed according current guidelines, specific clinical care and patients' characteristics could have biased the analysis.
IVT was less frequently administered in the medical group, the major reason being time from symptom onset >4 hours 30 minutes. The present findings are derived from observational analyses which are subject to well-known limitations. The first is the potential for confounding by measured or unmeasured variables, which cannot be ruled out, even after propensity score-matching/adjustment. A second limitation was the presence of missing data in some covariates, including in the propensity score-calculation. Although we used multiple imputations to handle missing data as appropriate, 30 we could not exclude that missing data could introduce a bias in estimates. Because no formal study sample size was calculated, we could not exclude that some differences may have been overlooked because of the lack of adequate statistical power. In a posterior power calculation, we calculated the smallest significant between-group difference (expressed as effect size using odd ratio) that our study sample size allowed us to detect with a 80% power, assuming an incidence of outcome of 60% in control group. Under these assumptions, we could detect an OR of 2.6 in the propensity score-matched cohort and 2.0 in propensity score-adjusted cohort.
Different Low NIHSS and Different Symptoms?
We did not explore the type of initial deficit as a predictor of outcome in our patients. Publications on this point report 
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various results, with studies showing no correlation between the type of deficit and outcome in patients with minor stroke, others showing that the type of deficit could be a predictor of poor outcome after minor stroke. 31 The NIHSS may not be adequate to assess severity of minor stroke on admission. Indeed, a low NIHSS does not mean a lack of handicap, and for example, complete hemianopia (NIHSS score at 2) is a symptom associated with severe disability. Similarly, distal hand paresis is not included in this score and a NIHSS score of 3 could be a minor but relevant deficit (ie, aphasia). Furthermore, other outcomes could be used when designing randomized studies for this subgroup of patients. Both the NIHSS drop at day 1 and the NIHSS shift between discharge and admission could be of interest, as well as the quality life score at 3 months.
Conclusions
Our multicenter case-control study shows that patients with NIHSS score of <8 and LVO in the anterior circulation having undergone MT or BMT achieve excellent and favorable functional outcomes at 3 months in similar proportions. However, differences in baseline characteristics were present between the 2 groups, highlighting the urgent need for randomized clinical trials evaluating MT for MMSP harboring LVO.
